Navigation Links
Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera
Date:9/22/2008

SAN FRANCISCO, Sept. 22 /PRNewswire/ -- Napo Pharmaceuticals (LSE: NAPL/NAPU) today announces positive clinical data on the effectiveness of crofelemer from a study for CRO-ID in treating severely ill cholera patients in conjunction with an antibiotic and rehydration therapy.

A double-blind placebo-controlled study was conducted in one hundred (100) patients with confirmed severe cholera. Patients were randomized to placebo or 125 mg crofelemer every 6 hours or 250 mg crofelemer every 6 hours in a 1:2:2 randomization scheme. This single center trial was conducted at the International Centre for Diarrhoeal Disease Research (ICDDR, B) in Dhaka, Bangladesh, popularly known as the "cholera hospital" for the state-of-the-art treatment of cholera patients.

The purpose of the trial was to obtain a therapeutic proof-of-concept in the treatment of cholera, by a reduction in the life-threatening fluid loss characteristic of cholera infection. In addition to receiving crofelemer, all patients received a single oral dose of azithromycin and rehydration therapy. These severely ill cholera patients, even when receiving the antibiotic azithromycin and rehydration therapy (but not crofelemer), averaged approximately 8.5 liters of stool volume output during the first 24 hour period. The primary endpoint in this study was the reduction in stool volume output normalized to the body weight of the cholera patients.

Following the exclusion of three outlier patients, the data demonstrates that a crofelemer dose of 125 mg every 6 hours reduced the amount of stool volume output normalized to body weight by 32% (p=0.028, Mann-Whitney test) in the first 6 hour period (0-6 hours). A 31% reduction in normalized stool volume output was also observed during the first 12 hour period (0-12 hours) with crofelemer 125 mg every 6 hours (p=0.072, Mann-Whitney test). The higher dose of crofelemer (250 mg every 6 hours) also showed a trend towards significance in the first 12
'/>"/>

SOURCE Napo Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
2. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
3. Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
4. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
5. Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
6. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
7. Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial
8. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
9. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
10. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
11. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... ORLEANS , May 22, 2013 ... for commercially-insured patients with Type 2 diabetes, while ... to improve health outcomes and can lead to ... presented at the International Society for Pharmacoeconomics and ... The two studies, sponsored by Valeritas, makers ...
(Date:5/22/2013)... ALISO VIEJO, Calif. , May 22, 2013  Avanir ... company management will present an overview of the company at ... Health Care Conference , Presentation date: Wednesday May 29, ... , Jefferies 2013 Global Healthcare Conference , Presentation ... a.m. E.T. A live ...
(Date:5/22/2013)... -- Grifols, a global healthcare company based in ... demonstrating that a higher dose of PROLASTIN © -C ... alpha 1 protein in patients with alpha 1 ... the normal range for healthy individuals. AAT deficiency is ... the alpha 1 proteinase inhibitor (A1PI) protein can ...
Breaking Medicine Technology:Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4
... , PITTSBURGH , Feb. ... how patients and doctors work together to fight cancer.  Now, ... promising results which can help to determine individual cancer treatment ... test produced by Precision Therapeutics, Inc., a life sciences company ...
... SAN FRANCISCO, Calif. , Feb. 3 Poniard Pharmaceuticals, ... oncology therapies, today announced that Ronald A. Martell has ... Jerry McMahon , Ph.D., who will remain as non-executive chairman of ... DVM, Ph.D., has been named president and chief medical officer. ...
Cached Medicine Technology:Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions 2Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions 3Poniard Pharmaceuticals Announces Management Changes and Reduction in Force 2Poniard Pharmaceuticals Announces Management Changes and Reduction in Force 3Poniard Pharmaceuticals Announces Management Changes and Reduction in Force 4
(Date:5/22/2013)... be reaping enormous income for patients whose hospital ... in their intensive care units. , In a ... American Journal of Medical Quality , the researchers ... avoidable central line-associated bloodstream infection (CLABSI) costs nearly ... similar infection-free patient. Moreover, hospitals earn nearly nine ...
(Date:5/22/2013)... 2013 Recent tragedies including the ... school shooting in Newtown, Connecticut all resulted in ... , Emergency medical practitioners train to respond to ... Medical Services for Children (EMSC) Program specifically provides ... the youngest patients. It is estimated 30 million ...
(Date:5/22/2013)... FL (PRWEB) May 22, 2013 Space ... on as a sponsor for this weekend's I Talk to ... place at 8:00 am at Cocoa Riverside Park in Cocoa, ... through the I Talk to Strangers social movement. , As ... runners and walkers to participate in the event. Additionally, they ...
(Date:5/22/2013)... Pamela Isom, President and CEO of ... Journal’s 2013 Women of Influence Award in recognition for ... The reception took place on Thursday, May 2 at ... is particularly humbling for the 5,000 people ICE Safety ... is to recognize the four to nine lives saved ...
(Date:5/22/2013)... Homeopathic Vibes is implementing new store hours ... the store during normal hours. On Wednesdays, they will now ... accommodate some of our patients who work shifts that won’t ... on Saturdays,” says owner and homeopathic consultant, Harminder Singh. Their ... p.m. Monday through Friday; weekends are by appointment only. ...
Breaking Medicine News(10 mins):Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care 2Health News:Space Girl Organics to Sponsor May 25 Miracle Run/Walk 2Health News:Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award 2Health News:Homeopathic Vibes Now Open Late on Wednesdays 2
... Specialists Available to Comment on Role of ... PHILADELPHIA, Oct. 15 Today,s news from ... overall decline in cancer,deaths in the United ... colorectal cancer. Many of the nation,s leading ...
... LARGO, Fla., Oct. 15 Dynamic Health ... distributor in,the sports nutrition product and performance drink ... Merger with the Florida Secretary of,State today as ... GeoPharma, Inc.,(Nasdaq: GORX ) ("GeoPharma"), effective Tuesday, ...
... 15 Speaker Nancy Pelosi,issued the following statement ... Bush,s veto of the State Children,s Health Insurance ... the House who have not already joined,this bipartisan ... vote,and to stand with 10 million children and ...
... The Health Care,Compliance Association (HCCA) will host ... for hospitals and for physicians,outlined in the U.S. ... General (OIG) 2008 Work Plan. It is an ... vital two-part audio/web conference will provide an in-depth,review ...
... Renews Commitment to Darfur, STAMFORD, Conn., Oct. 15 ... than $7,billion in aid to people in need around ... President and CEO Curt Welling announced the milestone at,the ... at Westchester County Airport on Saturday., "I am ...
... SET platform seen as having,potential clinical application for the noninvasive ... ... Masimo, the inventor,of Pulse CO-Oximetry and Read-Through Motion and Low ... study,presented today at the 2007 American Society of Anesthesiologists (ASA),Meeting ...
Cached Medicine News:Health News:Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma 2Health News:Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma 3Health News:Critical HCCA Web/Audio Conference Will Review Office of Inspector General Compliance Concerns Outlined in FY 2008 Work Plan 2Health News:AmeriCares Passes $7 Billion Mark in Aid Distributed 2Health News:Breaking Study: Masimo Pleth Variability Index (PVI) Shown Effective in Noninvasive Detection of Changes in Ventricular Preload and Fluid Volume 2Health News:Breaking Study: Masimo Pleth Variability Index (PVI) Shown Effective in Noninvasive Detection of Changes in Ventricular Preload and Fluid Volume 3Health News:Breaking Study: Masimo Pleth Variability Index (PVI) Shown Effective in Noninvasive Detection of Changes in Ventricular Preload and Fluid Volume 4
... channel platelet aggregation profiler combined with a ... with Microsoft WindowsTM, the PAP-4CD has real ... storage of test results, plus simplified data ... are available: chromogenic assays, von willebrand assay ...
Express Elyte Systems....
Iron / TIBC (Ferrozine). Storage temp: 2 - 8 C. Linearity: 0 - 500 ug/dl. Expected values: from TIBC 250 - 400 ug/dl, from Iron 40 - 160 ug/dl. Available with Calibrator and Number of test are 100....
For the quantitative determination of iron, total iron-binding capacity in human serum....
Medicine Products: